Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy

Yurdaydin, Cihan; Abbas, Zaigham; Buti, Maria; Cornberg, Markus; Esteban, Rafael; Etzion, Ohad; Ganes, Edward; Gish, Robert; Glenn, Jeffrey; Hamids, Saeed; Heller, Theo; Koh, Christopher; Lampertico, Pietro; Lurie, Yoav; Manns, Michael; Parana, Raymundo; Rizzetto, Mario; Urban, Stephan; Wedemeyer, Heiner; Wranke, A.; Borzacov, Pinheiro; Lobato, C.; Hamid, S.; Ceausu, E.; Dalekos, G.; Turcanu, A.; Niro, G.; Lubna, F.; Abbas, M.; Ingiliz, P.; Ferenci, P.; Vanwolleghem, T.; Hayden, T.; Dashdorj, N.; Motoc, A.; Hardtke, S.

doi:10.1016/j.jhep.2018.12.022

Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy

Yurdaydin C., Abbas Z., Buti M., Cornberg M., Esteban R., Etzion O., ...Daha Fazla

JOURNAL OF HEPATOLOGY, cilt.70, sa.5, ss.1008-1015, 2019 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 70 Sayı: 5
Basım Tarihi: 2019
Doi Numarası: 10.1016/j.jhep.2018.12.022
Dergi Adı: JOURNAL OF HEPATOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1008-1015
Anahtar Kelimeler: Hepatitis D, Treatment endpoints, Surrogate marker, New treatment approaches, PEGYLATED INTERFERON THERAPY, D-VIRUS, B-VIRUS, CLINICAL-TRIAL, MYRCLUDEX B, OPEN-LABEL, HDV, INFECTION, LONAFARNIB, RNA
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Ankara Üniversitesi Adresli: Evet

Özet

Chronic hepatitis delta represents the most severe form of chronic viral hepatitis. The current treatment of hepatitis delta virus (HDV) infection consists of the use of interferons and is largely unsatisfactory. Several new compounds are currently in development for the treatment of HDV infection. However, surrogate markers that can be used to develop clinical endpoints in HDV infection are not well defined. In the current manuscript, we aimed to evaluate the existing data on treatment of HDV infection and to suggest treatment goals (possible "trial endpoints") that could be used across different clinical trials. (C) 2018 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.